Matthew P. Holtzman

University of Pittsburgh — United States

Medicine · Health Sciences

35h-index5.0kcitations132works6.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Intraperitoneal and Appendiceal Malignancies(54), Appendicitis Diagnosis and Management(38), Ovarian cancer diagnosis and treatment(27), Cancer Immunotherapy and Biomarkers(24), Immunotherapy and Immune Responses(23)

Publications129 total

TP53 Alterations Are an Independent Adverse Prognostic Indicator in Pseudomyxoma Peritonei of Appendiceal Origin Following Cytoreductive Surgery and Intraperitoneal Chemotherapy
Applied immunohistochemistry & molecular morphology·2025
Patient Perspectives of Fertility Following Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy: An Opportunity for Improved Perioperative Counseling
Journal of Surgical Research·2025· 2 citedOpen Access
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Cancer Cell·2024· 42 citedOpen Access
Microsatellite instability should not determine candidacy for cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in patients with peritoneal metastases from colorectal cancer
Journal of Gastrointestinal Surgery·2024· 1 cited
Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).
Journal of Clinical Oncology·2024· 8 cited
Reduction in Postoperative Opioid Requirement Associated With Use of the NSS-2® Bridge Device, a Disposable Auriculo-Nerve Field Stimulator, and Factors Affecting the Response in Cancer Patients Undergoing Abdominal Surgical Procedures
2024Open Access
ASO Visual Abstract: Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases
Annals of Surgical Oncology·2024
Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases
Annals of Surgical Oncology·2024· 9 cited
Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma
SSRN Electronic Journal·2024Open Access
ASO Visual Abstract: Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases
Annals of Surgical Oncology·2023
Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases
Annals of Surgical Oncology·2023· 10 citedOpen Access
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Data from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Supplementary figure legend 2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Data from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Supplementary Figure S1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Supplementary Figure S1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023Open Access
page 1 of 7Next →

Frequent Co-authors

David L. Bartlett(35), Herbert J. Zeh(34), Haroon A. Choudry(28), James F. Pingpank(24), Steven A. Ahrendt(20), Heather Jones(19), Amer H. Zureikat(18), Lekshmi Ramalingam(16), James Pingpank(11), Reetesh K. Pai(11), Yongli Shuai(7), Deepa Magge(6), Melissa E. Hogg(6), Jan Franko(5), Mazen S. Zenati(5), Steven S. Ahrendt(5), David L. Bartlett(4), Frances Austin(4), Arun Mavanur(4), Charles K. Brown(3)